tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Ultragenyx (RARE) Earnings Call Highlights Growth and Challenges
Company AnnouncementsUltragenyx (RARE) Earnings Call Highlights Growth and Challenges
3d ago
RARE
Ultragenyx Pharmaceutical Positioned for Success with Strategic Financing and Promising Setrusumab Trials
PremiumRatings
Ultragenyx Pharmaceutical Positioned for Success with Strategic Financing and Promising Setrusumab Trials
4d ago
RARE
Positive Outlook for Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Financial Strength and Product Growth
PremiumRatings
Positive Outlook for Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Financial Strength and Product Growth
4d ago
RARE
Ultragenyx price target lowered to $75 from $86 at TD Cowen
PremiumThe Fly
Ultragenyx price target lowered to $75 from $86 at TD Cowen
4d ago
RARE
Ultragenyx Reports Q3 2025 Financial Results
PremiumCompany Announcements
Ultragenyx Reports Q3 2025 Financial Results
4d ago
RARE
Closing Bell Movers: AMD falls 4% on earnings, Trex, Pinterest down sharply
PremiumThe FlyClosing Bell Movers: AMD falls 4% on earnings, Trex, Pinterest down sharply
4d ago
GO
KD
Ultragenyx sells additional 25% of Crysvita royalty interest for $400M
Premium
The Fly
Ultragenyx sells additional 25% of Crysvita royalty interest for $400M
4d ago
RARE
Ultragenyx Signs $400M Royalty Purchase Agreement
Premium
Company Announcements
Ultragenyx Signs $400M Royalty Purchase Agreement
4d ago
8K
RARE
Ultragenyx reports Q3 EPS ($1.81), consensus ($1.21)
PremiumThe Fly
Ultragenyx reports Q3 EPS ($1.81), consensus ($1.21)
4d ago
RARE
Ultragenyx affirms 2025 revenue outlook $640M-$670M, consensus $657.39M
PremiumThe Fly
Ultragenyx affirms 2025 revenue outlook $640M-$670M, consensus $657.39M
4d ago
RARE
RARE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RARE Upcoming Earnings Report: What to Expect?
7d ago
RARE
Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome
PremiumCompany Announcements
Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome
10d ago
8K
RARE
Ultragenyx announces first patient dosed in Aurora study
PremiumThe FlyUltragenyx announces first patient dosed in Aurora study
10d ago
RARE
Ultragenyx price target lowered to $74 from $79 at BofA
Premium
The Fly
Ultragenyx price target lowered to $74 from $79 at BofA
18d ago
RARE
Ultragenyx placed on ‘Positive Catalyst Watch’ at JPMorgan
Premium
The Fly
Ultragenyx placed on ‘Positive Catalyst Watch’ at JPMorgan
1M ago
RARE
Ultragenyx appoints Eric Olson Chief Business Officer
PremiumThe Fly
Ultragenyx appoints Eric Olson Chief Business Officer
1M ago
RARE
Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
PremiumRatings
Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
2M ago
RARE
Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
PremiumRatings
Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
2M ago
RARE
Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating
PremiumRatings
Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating
2M ago
RARE
Buy Rating Affirmed for Ultragenyx Pharmaceutical: Promising Phase III Results of DTX401 Gene Therapy
PremiumRatingsBuy Rating Affirmed for Ultragenyx Pharmaceutical: Promising Phase III Results of DTX401 Gene Therapy
2M ago
RARE
Ultragenyx Reports Positive Phase 3 Gene Therapy Results
Premium
Company Announcements
Ultragenyx Reports Positive Phase 3 Gene Therapy Results
2M ago
8K
RARE
Ultragenyx announces longer-term result from DTX401 AAV gene therapy study
Premium
The Fly
Ultragenyx announces longer-term result from DTX401 AAV gene therapy study
2M ago
RARE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >